AcelRx Pharmaceuticals Inc. (ACRX) Shares Down 4.1%
AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX)’s share price traded down 4.1% during mid-day trading on Thursday . The company traded as low as $3.02 and last traded at $3.02, with a volume of 115,036 shares changing hands. The stock had previously closed at $3.15.
A number of equities analysts recently issued reports on the stock. RBC Capital Markets reiterated a “positive” rating and issued a $6.00 target price on shares of AcelRx Pharmaceuticals in a research report on Tuesday, August 16th. Cowen and Company reissued a “hold” rating on shares of AcelRx Pharmaceuticals in a report on Friday, July 29th. Jefferies Group reissued a “buy” rating on shares of AcelRx Pharmaceuticals in a report on Wednesday, August 10th. Stifel Nicolaus downgraded shares of AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, August 5th. Finally, HC Wainwright reissued a “buy” rating on shares of AcelRx Pharmaceuticals in a report on Monday, August 1st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $7.30.
The company’s 50 day moving average price is $3.33 and its 200-day moving average price is $3.33. The stock’s market capitalization is $140.01 million.
AcelRx Pharmaceuticals (NASDAQ:ACRX) last issued its quarterly earnings data on Thursday, July 28th. The specialty pharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.22) by $0.02. The business earned $4.53 million during the quarter, compared to the consensus estimate of $2.17 million. On average, equities research analysts predict that AcelRx Pharmaceuticals Inc. will post ($0.91) EPS for the current fiscal year.
AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.